Effect of Nicardipine on Renal Function in Deliberate Hypotension
Primary Purpose
Spinal Stenosis
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Nicardipine
Sponsored by
About this trial
This is an interventional prevention trial for Spinal Stenosis
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing anterior or posterior spine interbody fusion
Exclusion Criteria:
- Patients with American Society of Anesthesiologists physical status III or IV
- Liver dysfunction with aspartate transaminase/alanine transaminase greater than 60/60 IU/L
- Cerebrovascular disease
- Anemia of less than hematocrit 24%
- Diabetes mellitus
- Severe malnutrition
- those diuretics or antihypertensive drugs
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Nicardipine and Remifentanil
Remifentanil
Arm Description
intravenous nicardipine and remifentanil during deliberate hypotension
intravenous remifentanil during deliberate hypotension
Outcomes
Primary Outcome Measures
creatinine clearance
serum cystatin C
urine output
fractional excretion of sodium
Secondary Outcome Measures
Risk, injury, failure, loss, and end stage renal disease (RIFLE) criteria
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02271191
Brief Title
Effect of Nicardipine on Renal Function in Deliberate Hypotension
Official Title
Effect of Nicardipine on Renal Function in Deliberate Hypotension
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yonsei University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study was to demonstrate the effect of nicardipine on renal function with creatinine clearance, serum cystatin C, urine output and fractional excretion of sodium during deliberate hypotension for spine surgery.
Detailed Description
To induce deliberate hypotension, pharmacological agents such as inhalation anesthetics, calcium channel blockers, beta-adrenergic blockers have been used alone or in combination. Nicardipine, classed as a calcium channel blocker, has a peripheral vasodilator effect via relaxation of smooth muscle fiber and sympathetic nerve inhibition. Nicardipine expands the renal artery and increases glomerular filtration rate. Previous studies reported the renal protective effect of nicardipine in cardiac surgery with cardiopulmonary bypass and robot-assisted laparoscopic surgery.
The aim of this study was to demonstrate the effect of nicardipine on renal function with creatinine clearance , serum cystatin C, urine output and fractional excretion of sodium during deliberate hypotension for spine surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Stenosis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nicardipine and Remifentanil
Arm Type
Active Comparator
Arm Description
intravenous nicardipine and remifentanil during deliberate hypotension
Arm Title
Remifentanil
Arm Type
Placebo Comparator
Arm Description
intravenous remifentanil during deliberate hypotension
Intervention Type
Drug
Intervention Name(s)
Nicardipine
Other Intervention Name(s)
Perdipine
Intervention Description
nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
Primary Outcome Measure Information:
Title
creatinine clearance
Time Frame
after deliberate hypotension, and POD1
Title
serum cystatin C
Time Frame
before deliberate hypotension, after deliberate hypotension, and POD1
Title
urine output
Time Frame
after deliberate hypotension, and POD1
Title
fractional excretion of sodium
Time Frame
before deliberate hypotension, after deliberate hypotension, and POD1
Secondary Outcome Measure Information:
Title
Risk, injury, failure, loss, and end stage renal disease (RIFLE) criteria
Time Frame
before deliberate hypotension, after deliberate hypotension, and POD1
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients undergoing anterior or posterior spine interbody fusion
Exclusion Criteria:
Patients with American Society of Anesthesiologists physical status III or IV
Liver dysfunction with aspartate transaminase/alanine transaminase greater than 60/60 IU/L
Cerebrovascular disease
Anemia of less than hematocrit 24%
Diabetes mellitus
Severe malnutrition
those diuretics or antihypertensive drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chul Ho Chang, MD, PhD
Organizational Affiliation
Department of Anesthesiology and Pain Medicine, Gangnam Severance Hospital, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Republic of Korea
Official's Role
Study Chair
12. IPD Sharing Statement
Learn more about this trial
Effect of Nicardipine on Renal Function in Deliberate Hypotension
We'll reach out to this number within 24 hrs